Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aardvark Therapeutics

8.75
-0.3400-3.74%
Volume:366.00
Turnover:3.31K
Market Cap:187.11M
PE:-13.50
High:9.19
Open:9.19
Low:8.75
Close:9.09
Loading ...

Aardvark Therapeutics Is Maintained at Outperform by RBC Capital

Dow Jones
·
Yesterday

Aardvark Therapeutics Inc trading resumes

TIPRANKS
·
Yesterday

Aardvark Therapeutics Inc trading halted, volatility trading pause

TIPRANKS
·
Yesterday

RBC Trims Price Target on Aardvark Therapeutics to $20 From $21, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Yesterday

BRIEF-Aardvark Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights

Reuters
·
Yesterday

Aardvark Therapeutics Q1 EPS $(0.71) Down From $(0.55) YoY

Benzinga
·
Yesterday

Aardvark Therapeutics Reports Q1 2025 Results: Net Loss Widens to $9.3M; R&D Expenses Surge

Reuters
·
Yesterday

Aardvark Therapeutics Inc - as of March 31, 2025, Aardvark Had Cash, Cash Equivalents, and Short-Term Investments of $151.3 Mln

THOMSON REUTERS
·
Yesterday

Aardvark Therapeutics Price Target Maintained With a $50.00/Share by Cantor Fitzgerald

Dow Jones
·
01 Apr

Aardvark Therapeutics FY24 EPS (5.15) Down From ($1.82) YoY

Benzinga
·
01 Apr

Press Release: Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights

Dow Jones
·
01 Apr

BUZZ-Ultragenyx Pharma up after JPMorgan PT raise

Reuters
·
27 Mar

Aardvark Therapeutics Is Maintained at Buy by B of A Securities

Dow Jones
·
27 Mar

Aardvark Therapeutics price target raised to $26 from $22 at BofA

TIPRANKS
·
27 Mar

Aardvark Therapeutics Inc : Bofa Global Research Initiates Coverage With Buy Rating; Price Objective $22

THOMSON REUTERS
·
10 Mar

BofA Initiates Aardvark Therapeutics at Buy With $22 Price Target

MT Newswires Live
·
10 Mar

Aardvark Therapeutics Initiated at Buy by B of A Securities

Dow Jones
·
10 Mar

Morgan Stanley Initiates Aardvark Therapeutics at Overweight

MT Newswires Live
·
10 Mar

Cantor Fitzgerald Initiates Aardvark Therapeutics at Overweight With $50 Price Target

MT Newswires Live
·
10 Mar

RBC Initiates Aardvark Therapeutics at Outperform With $21 Price Target, Speculative Risk Qualifier

MT Newswires Live
·
10 Mar